Left ventricular outflow tract (LVOT) obstruction is an integral component of hypertrophic cardiomyopathy (HCM). Both chemical myomectomy and alcohol septal ablation (ASA) have been shown effective in the reduction of residual gradients and symptoms in several studies and clinical registries, and are normally reserved for patients who continue experiencing symptoms despite medical treatment. Even though…
Alcohol Septal Ablation and Pacemaker Implantation: Results After 5 Years
Alcohol septal ablation is used to treat patients with obstructive hypertrophic cardiomyopathy. A significant complication in this intervention is atrioventricular block requiring pacemaker implantation in 7% to 20% of cases. Current evidence is limited for clinical results at follow-up for these patients. The aim of this study was to evaluate the results for patients with…
Prognosis After Pacemaker Implantation in Alcohol Septal Ablation
One of the main complications of alcohol septal ablation (ASA) is the alteration in the conduction system, which could lead to permanent pacemaker (PPM) implantation. This is mainly due to the relationship between septal perfusion and the conduction system (especially the right bundle branch). The incidence reported in the literature is 7% to 20% of…
Hypertrophic Cardiomyopathy: Analyzing a Historical Series
75% of patients with hypertrophic Cardiomyopathy present symptoms. An important group responds very well to pharmacological treatment with betablockers and calcium antagonists, and those who do not respond, or do not tolerate these drugs, receive, at present, surgery as elective treatment. There is also alcohol septal ablation as an alternative strategy, which different studies have…